Ziagen
Ziagen

6.28
A generic medicine indicated for HIV. Inhibits viral growth enzymes to assist in viral load suppression and support long-term systemic function.


Ingredient
Availability
In Stock
Delivery Time
Airmail (14-21 days) | Trackable (5-9 days)
Shipped in a discreet, unmarked envelope with all required documents enclosed.

Product Sheet

Active Ingredient(s)
Abacavir sulfate
Reference Brand
Abacavir
Product Origin
Generic Alternative
Reference Manufacturer
ViiV Healthcare
Product Form
Tablet
Regulatory Classification
Prescription Only Medicine
Primary Category
Antivirals
Product Category
Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI)
Pharmacological Class
Antiretroviral
Manufacturer Description
Designed to support retroviral suppression to manage CD4 counts and target viral reverse transcription.
Mechanism of Action
Incorporates into growing viral DNA, acting as a chain terminator to prevent reverse transcriptase replication.
Route of Administration
Oral
Onset Time
2–4 weeks
Duration
12–24 hours
Contraindications
HLA-B*5701 allele presence, Moderate to severe hepatic impairment, Hypersensitivity to abacavir
Severe Adverse Events
Abacavir hypersensitivity reaction — requires immediate medical attention, Lactic acidosis — requires immediate medical attention
Common Side Effects
Nausea, Headache, Fatigue
Uncommon Side Effects
Vomiting, Diarrhea, Insomnia
Drug Interactions
Alcohol, Methadone
Pregnancy Safety Warnings
TGA Category C: Deemed generally safe. Breastfeeding: Avoid to prevent viral transmission.
Age Restrictions
Approved for infants over three months, children, and adults.
Storage Guidelines
Store below 25°C. Keep dry.
Related Products
Information related to Ziagen is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
Categories
where to access Osteoporosis Treatment Australia - Rocaltrol Australia